|Bid||325.65 x N/A|
|Ask||325.85 x N/A|
|Day's range||323.00 - 327.15|
|52-week range||241.17 - 357.65|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||27.15|
|Earnings date||02 Aug 2023|
|Forward dividend & yield||0.05 (1.45%)|
|Ex-dividend date||16 Mar 2023|
|1y target est||361.81|
After a fairly weak start to life as a stock exchange-listed company, could Haleon shares be a screaming buy at their current share price? The post Up 32%, are Haleon shares the best FTSE 100 buy in June? appeared first on The Motley Fool UK.
HLN vs. SYK: Which Stock Is the Better Value Option?
With its stock down 8.9% over the past month, it is easy to disregard Haleon (LON:HLN). We, however decided to study...
The latest investor updates on stocks that are trending on Friday.
LONDON (Reuters) -Despite price increases, Haleon's roster of consumer health products have largely kept cheaper private-label competition at bay, Haleon chief financial officer Tobias Hestler said on Wednesday. The world's biggest standalone consumer health company, comprising assets from GSK and Pfizer, sells non-prescription drugs, vitamins and oral care products and reported quarterly profit below expectations as higher costs squeezed margins. Cost inflation has hit Haleon along with other consumer staples, rising initially during the COVID-19 pandemic and then exacerbated by Russia's invasion of Ukraine.
Pfizer's plan to sell its Haleon stake is not a surprise, the consumer health company's finance chief Tobias Hestler told Reuters on Wednesday. London-listed Haleon was carved out as an independent company in July and comprises consumer health assets once owned by GSK and Pfizer. Pfizer, which has a 32% stake in the maker of Sensodyne toothpaste and Panadol painkillers, told the Financial Times on Tuesday that it intends to offload that stake in a "slow and methodical" manner within months.
Key Insights The projected fair value for Haleon is UK£3.15 based on 2 Stage Free Cash Flow to Equity Haleon's UK£3.45...
Haleon plc ( LON:HLN ) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock...
Shareholders might have noticed that Haleon plc ( LON:HLN ) filed its annual result this time last week. The early...
Consumer healthcare group Haleon's Chief Executive Brian McNamara said on Thursday he does not expect to announce any acquisitions or divestments imminently, amid analyst concerns its 2023 cost forecasts could hit consensus profit estimates. McNamara told Reuters that both types of transactions were on the cards, but added "there's certainly nothing imminent that is out there that I would talk about today". Haleon, carved out of British drugmaker GSK in July in the biggest listing in Europe for more than a decade, is the world's biggest standalone consumer health business selling non-prescription drugs, vitamins and oral care products.
A look at the shareholders of Haleon plc ( LON:HLN ) can tell us which group is most powerful. The group holding the...
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Market noise has been loud this year and it has been difficult for investors to look beyond the hysteria whipped up by their peers to focus on information and fundamentals. Sentiment has also been highly changeable, which has led to volatile stock prices that in many cases materially diverge from underlying business valuations.
Haleon ( LON:HLN ) Third Quarter 2022 Results Key Financial Results Net income: UK£345.0m (up by UK£345.0m from 3Q...
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
The GSK group posted an 18% rise in sales to £7.8bn over the third quarter.
GSK now expects constant currency annual sales growth of between 8% and 10% and a rise in underlying earnings of 15%-17%.
Does the October share price for Haleon plc ( LON:HLN ) reflect what it's really worth? Today, we will estimate the...
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
The British economy has descended into turmoil after the Government’s mini-Budget triggered a historic rout in the bond market – but some investment experts think this has created buying opportunity at rock-bottom prices.
The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years
The company, which owns health products Sensodyne and Panadol, posted a 13.4% rise in its revenue to £5.2 billion in the first half of the year.
LONDON (Reuters) -Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday. Zantac, originally marketed by a forerunner of GSK , has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers. Haleon, spun out of GSK as an independent company in July as the world's biggest standalone consumer health business, comprises consumer health assets once owned by GSK and Pfizer.